GlassScriptPhysician profile
Jean B Stretton
NPI 1679532618
$2,572.85
in general payments reported to CMS, 2019-2025
35 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $612 · 2021: $569 · 2022: $489 · 2023: $329 · 2024: $218 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $424.84 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $260.88 | 2019-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.63 | 2020-2023 | Tradjenta, Synjardy, Jardiance |
| Pfizer INC. | $231.36 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $134.98 | 2019-2024 | Gardasil, Gardasil 9 |
| Lilly USA, LLC | $107.91 | 2020-2024 | Zepbound |
| Amarin Pharma, INC. | $101.03 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $95.82 | 2019-2024 | Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $90.46 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $86.99 | 2020-2022 | |
| Glaxosmithkline, LLC. | $76.53 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $73.90 | 2019-2025 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $65.42 | 2021-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $54.64 | 2019-2020 | |
| Exact Sciences Corporation | $52.03 | 2023-2025 | Cologuard Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $44.46 | 2020 | |
| Adlon Therapeutics L.P. | $44.37 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.76 | 2020-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $32.52 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.62 | 2022 | |
| Abbott Laboratories | $25.06 | 2024 | Octrode |
| Teva Pharmaceuticals USA, INC. | $23.87 | 2020 | |
| Dexcom, INC. | $20.93 | 2021 | |
| Boston Scientific Corporation | $20.71 | 2024 | Bodyguardian |
| Nestle Healthcare Nutrition INC. | $20.63 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.41 | 2020 | |
| Xeris Pharmaceuticals, INC. | $19.40 | 2023 | Gvoke Hypopen |
| Inari Medical, INC. | $19.24 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Corium, LLC | $19.13 | 2022 | |
| Eisai INC. | $18.93 | 2020 | |
| Circassia INC. | $15.88 | 2019 | |
| Sanofi Pasteur INC. | $15.35 | 2019 | |
| Allergan, INC. | $12.60 | 2020 | |
| Bausch Health US, LLC | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Stretton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.